Julya Zuenkova
Business Development Director
Xstrahl Group
COVID-19 significantly impacted how providers reach out to patients. Besides, there has been a series of changes in the reimbursement and funding of medical technologies and procedures. These aspects created opportunities to address new market needs and leverage data and learning to deliver more value to a growing network of payers, providers, and patients. Welcome to the new era of Network Value.
Ernesto M. Nogueira
CEO and Founder
ValueConnected
Claus Schaffrath
Managing Director, MD squared
Katarzyna Kolasa
Sr. Consultant Health Economics, MD squared
Professor & Head of Health Economics & Healthcare Management Division, Kozminski University
In today's demanding world of national requirements, how can companies develop the right evidence portfolio to succeed? How can they integrate evidence for payers with their regulatory studies? This in depth review will discuss core principles in evidence development for diagnostics and therapeutic medical devices, and how these concepts can align with the requirements of the major global markets -- the UK, France, Germany, Japan and the USA. Learn about the evolving landscape of evidence demands in:
Stephen Hull
Principal and Founder
Hull Associates